4/A: BridgeBio Pharma Director Amends Disclosure of 2021 Stock Acquisitions
Insider Transaction Disclosure Amendment
Hannah Valantine, a Director at BridgeBio Pharma, Inc., filed an amended Form 4 to clarify direct and indirect common stock acquisitions made in December 2021.
Summary
- Hannah Valantine, a Director of BridgeBio Pharma, Inc. (BBIO), filed an amended Statement of Changes in Beneficial Ownership (Form 4/A).
- The amendment pertains to transactions that occurred on December 28, 2021.
- Valantine directly acquired 1,542 shares of Common Stock at a price of $12.68 per share.
- An additional 796 shares of Common Stock were indirectly acquired by her spouse at a price of $13.16 per share.
- Following these reported transactions, Valantine beneficially owns 1,542 shares directly and 2,687 shares indirectly through her spouse.
Sentiment
Score: 5
Explanation: The document is a factual amendment to an insider transaction disclosure. While the underlying transaction (insider buying) is mildly positive, the filing itself is a neutral compliance update, albeit with a noted delay in original reporting.
Positives
- A director's acquisition of company shares, even if historical, can signal confidence in the company's future prospects.
Future Outlook
No forward-looking statements or guidance are provided in this insider transaction disclosure amendment.
Industry Context
This filing is a standard regulatory disclosure of insider stock transactions, common across all publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape, but rather details a specific director's equity holdings.
Related Party Transactions
- The document discloses indirect beneficial ownership of shares by Hannah Valantine's spouse, which is a common form of related party transaction in insider reporting.
Stakeholder Impact
- Shareholders: Provides transparency regarding a director's equity holdings and past transactions, which can influence investor sentiment regarding management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 12/28/2021 | Date of the common stock acquisition transactions by Hannah Valantine and her spouse. |
| 02/13/2024 | Date the original Form 4 was filed, which this document amends. |
| 06/30/2025 | Signature date of the reporting person on the amended filing. |
Keywords
BridgeBio Pharma, BBIO, SEC Form 4/A, Insider Trading, Stock Acquisition, Beneficial Ownership, Hannah Valantine, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.